Biosimilars Should Face Patent Challenges Only After Approval, Novartis Says
Executive Summary
Linking patent disputes to regulatory approval of follow-on biologics would provide no competitive benefit for patients and could discourage innovation, contends Robert Pelzer, head of Novartis' North American operations
You may also be interested in...
On The Trail Of Biosimilar Disclosure Scofflaws: FTC To Watch For Anti-Competitive Issues
As FDA prepares for another public hearing on the pathway, FTC says the rules requiring biosimilar applicants to share information with their reference product competitors could lead to anti-competitive issues and may be an ongoing concern.
Follow-On Biologic Stakeholders Agree On Patent Resolution, Differ On Details
Inclusion of a mechanism for patent dispute resolution in the pathway for approving follow-on biologics was supported by representatives on both sides of the FOB debate during a Federal Trade Commission workshop Nov. 21
Follow-On Biologic Stakeholders Agree On Patent Resolution, Differ On Details
Inclusion of a mechanism for patent dispute resolution in the pathway for approving follow-on biologics was supported by representatives on both sides of the FOB debate during a Federal Trade Commission workshop Nov. 21